Abstract: A microencapsulated enteric matrix composition and method for manufacture are provided. The microencapsulated enteric composition includes enteric material, such as sodium caseinate and soy protein, and a functional ingredient contained therein in a core. Further, the composition includes a first coating including zein and the second, outer coating including ethylcellulose. The microencapsulated enteric composition may be suitable for use in hot comestibles.

Abstract: A composition comprising a cannabinoid receptor binding agent contained in a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.

Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Abstract: The present invention relates to methods of diagnosing and treating prostate cancer, including metastatic prostate cancer. Related pharmaceutical compositions are also provided.

Abstract: The present invention provides compositions useful for transfecting cells (e.g., liver cells) to express ABCA1. The compositions described herein comprise a pharmaceutically acceptable aqueous carrier containing sonochemically-active microspheres together with a plasmid DNA construct encoding an active form of ABCA1 and at least one promoter for the expression thereof. Preferably, the sonochemically-active microspheres comprise, consist essentially of, or consist of gas bubbles (e.g., a fluorocarbon gas, such as octafluoropropane) encapsulated within protein-containing or lipid-containing shells (e.g., human serum albumin shells). The microspheres are disruptable by exposure to ultrasonic acoustic energy to release the encapsulated gas.

Abstract: A bone graft or biocomposite for treating osseous defects and neogenesis of bone which is a composite of a biodegradable polymer and granules of beta-tricalciumphosphate, further comprising as active ingredient and embedded in the biodegradable polymer a physiologically effective amount of underglycosylated recombinant human BSP as a multi-dental clathrate with a basic organic compound which simulataneously is active as a plasticizer for the biodegradable polymer. The biocomposite is moldable and shapeable, hardens rapidly in situ when placed by surgery or prosthetic dentistry and which furthers osseous repair and the healing of damage or diseased tissues and lesions.

Abstract: The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents.

Abstract: Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic FeO nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic FeO nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic FeO nanoparticles in water to oxidize FeO; and exposing the oxidized hydrophilic FeO nanoparticles to an acidic buffer to dissolve and remove interior unoxidized FeO portions, and thereby to form Fe3O4 nanoparticles having an interior space.

Abstract: The present invention relates to teriparatide peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of bone density. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprise at least one glutathione; and at least one teriparatide peptide that is non-covalently bound to the corona.

Abstract: Anti-RSV peptide and a segment thereof derived from a peptide sequence identified in the human RSV fusion protein precursor F0. Another anti-RSV agent is carboxylated gold nanoparticles. A method is provided for attaching peptides to the carboxylated gold particles to produce additional anti-RSV agents to prevent or inhibit infection by the respiratory syncytial virus (RSV) and related viruses, including the human immunodeficiency virus (HIV).

Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.

Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.

Abstract: The present invention discloses a cross-linked hyaluronic acid/collagen formulation which has improved composition for dermal filling and higher persistence than cross-linked collagen or HA alone. Also disclosed are methods for preparing cross-linked hyaluronic acid/collagen formulations and using such for augmenting soft tissues in mammals.

Abstract: The présent invention relates to cell-penetrating peptides characterized in that it comprises an amino acid séquence selected in the group consisting of X1LX2RALWX9LX3X9X4LWX9LX5X6X7X8, X1LX2LARWX9LX3X9X4LWX9LX5X6X7X8 and X1LX2ARLWX9LX3X9X4LWX9LX5X6X7X8, wherein X1 is beta-A or S, X2 is F or W, X3 is L, W, C or I, X4 is S, A, N or T, Xs is L or W, X6 is W or R, X7 is K or R, X8 is A or none, and X9 is R or S. Thèse peptides exhibit high efficiency, low toxicity and a natural tropism for lung tissues, and can be used either in simple complex with the cargo to be vectorised, or in nanoparticles comprising two layers of cell-pentrating peptides around the cargo.

Abstract: Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise a carbohydrate, insulin and/or a glutathione; and (b) the at least one agent to be delivered to the CNS. Methods of treatment and diagnosing CNS disorders utilising the nanoparticle delivery systems and related screening methods are also disclosed.

Abstract: A biodegradable iron oxide nanoparticle gel for hyperthermia treatment of cancer includes a polysaccharide-based carrier matrix and starch-coated iron oxide nanoparticles. The gel has sufficient deformability to integrate into a diffuse tumor site, adheres to tissue and has sufficient mechanical properties to remain in place during hyperthermia treatment. The gel releases iron oxide nanoparticles for uptake by cancerous cells at the tumor margin.

Abstract: The invention relates to a pharmaceutical composition comprising factor VII encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the group consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.

Abstract: Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule, such as a protein. The biologically active molecule is preferably released from the nanotube when the complex has been taken up in an endosome.

Abstract: The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic.

Abstract: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules. The carrier polymers also can be used in scaffolds for regenerative medicine.

Abstract: A method of synthesizing PHA nanocapsules as a protein carrier, particularly, the synthesis of PHA nanocapsules synthesized by a modified precipitation/solvent evaporation technique with neutralization. Specifically, the method comprises the steps of sonicating a first solution comprising a triblock PHA copolymer, stirring the first solution into a second solution to give a third solution, the second solution containing a protein, and the second solution being acidic. Further, the method comprises adding the third solution with a neutralizing agent to give a neutralized solution, and sonicating the neutralized solution to form a final solution, wherein the synthesized PHA nanocapsules containing the protein are formed in the final solution. Further, PHA nanocapsules encapsulated with the protein is used by administering the synthesized PHA nanocapsule to an animal in need thereof via the oral cavity.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Abstract: The present invention provides methods and compositions for treating cancer by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a nucleoside analog (e.g., gemcitabine) based upon levels of a nucleoside transporter (e.g., hENT1).

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: The present invention provides methods and compositions for treating cancer by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and/or b) a therapeutic agent (e.g., gemcitabine) based upon K-ras mutation status.

Abstract: A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.

Abstract: The present invention provides compositions (such as pharmaceutical compositions) comprising nanoparticles comprising albumin and paclitaxel. The compositions have a specific albumin polymer/monomer profile and are particularly suitable for use in treating diseases such as cancer.

Abstract: This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described.

Abstract: This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation.

Abstract: SP1 and modified SP1 variant polypeptides capable of forming reversible molecular associations with substances, compositions-of-matter comprising same, and uses thereof are provided.

Abstract: A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in E. coli using a small-ubiquitin-related fusion protein expression system and an E. coli strain used in practicing this method. Also disclosed is use of the picornaviral capsid protein complexes like thus prepared for eliciting immune responses.

Abstract: A composition comprising a cannabinoid receptor binding agent attached to a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.

Abstract: A microencapsulated enteric matrix composition and method for manufacture are provided. The microencapsulated enteric composition includes enteric material, such as sodium caseinate and soy protein, and a functional ingredient contained therein in a core. Further, the composition includes a first coating including zein and the second, outer coating including ethylcellulose. The microencapsulated enteric composition may be suitable for use in hot comestibles.

Abstract: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof.

Abstract: An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O2 directly (CDC OC), or hemoglobin can be adsorbed to provide a hemoglobin-based oxygen carrier (CDC HBOC). The delivery system allows the use of a variety of hemoglobins which differ in their oxygen dissociation profiles, including variant and mutant hemoglobins from other species. The delivery system is biocompatible and stable, and is able to irreversibly bind and hold large amounts of functional hemoglobin variants. The CDC HBOC and CDC OC provide a safe and effective blood substitute for combat casualty care, as well as being useful for oxygen delivery in other contexts.

Abstract: The disclosure is directed to a nanoparticle comprising a porous framework core including a porous framework material and a compound, and a lipid layer disposed on the surface of the porous framework core.

Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.

Abstract: The invention relates to the use of peptides, proteins, and other oligomers to provide a means by which normally quenched nanoparticle fluorescence may be recovered upon detection of a target molecule. Further, the inventive technology provides a structure and method to carry out detection of target molecules without the need to label the target molecules before detection. In another aspect, a method for forming arbitrarily shaped two- and three-dimensional protein-mediated nanoparticle structures and the resulting structures are described. Proteins mediating structure formation may themselves be functionalized with a variety of useful moieties, including catalytic functional groups.

Abstract: The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter.

Abstract: The present invention relates to a bone substitute comprising a core based on hydroxyapatite (HA), obtained from at least one porous wood, or based on collagen fibres and hydroxyapatite, and a shell, based on hydroxyapatite (HA) or silicon carbide (SiC), obtained from at least one wood having a lower porosity than the at least one wood of the core. The porous wood has a total porosity of between 60% and 95%, preferably between 65% and 85%, and it is selected from amongst the choices of rattan, pine, abachi and balsa wood. The wood of the shell has a porosity of between 20% and 60%, preferably between 30% and 50%. The bone substitute is utilized for the substitution and regeneration of bone, preferably for bones subjected to mechanical loads, such as long bones of the leg and arm, preferably the tibia, metatarsus, femur, humerus or radius.

Abstract: Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.

Abstract: The present invention relates to a small particle size composition comprising pancreatin containing digestive enzymes for use in patients in need, including pediatric, geriatric, and adult patients, particularly those patients with dysphagia or wherein enteral administration using such composition would be suitable. In addition, the invention is directed to the composition as particles, such as micropellets or microgranules having a high potency, high useable yield and at least 10%-90% of 400-800 ?m. Furthermore, the composition optionally has an improved enteric coating and concomitant improved stability and enzyme activity compared to conventional prepared enterically coated pancreatic enzyme particles.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.

Abstract: This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents.

Abstract: The present provide vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed on to a particle of metal salt and the resulting particle is essentially devoid of antigen.

Abstract: The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present applicators is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapules e.g. in the treatment of type 2 diabetes, weight disorders and diseases or conditions associated thereto, neurodegenerative disorders and diseases or conditions associated thereto, or for the treatment of disorders and diseases or conditions associated to apoptosis.

Abstract: The present invention relates to the provision of micron or sub-micron sized particles formed from one or more water-soluble crystals comprising a surface coating comprising one or more bioactive molecules wherein the particles are prepared such that in use the release of the bioactive molecule(s) is/are delayed and/or continually released over a period of time. Processes for the preparation of said particles, as well as the particles themselves are described, as well as uses of the particles.